following an abbreviated submission:
budesonide/formoterol (Symbicort® SMART®) is accepted for use within NHS Scotland.
Indication under review: the regular treatment of asthma where use of a combination (inhaled corticosteroid and a long-acting β2 adrenoceptor agonist is appropriate: patients not adequately controlled with inhaled corticosteroids and "as needed" short-acting β2 adrenoceptor agonists, or patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
This advice relates to the extension of the license for Symbicort maintenance and reliever therapy (SMART®) to adolescents aged 12 to <18 years.
SMC has previously accepted Symbicort maintenance and reliever therapy (SMART®) in adults.
|Drug Name:||budesonide-formoterol (Symbicort SMART)|
|SMC Drug ID:||1244/17|
|Manufacturer:||AstraZeneca UK Ltd|
|Indication:||Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. Treatment with buprenorphine oral lyophilisate is intended for use in adults and adolescents aged 15 years or over who have agreed to be treated for addiction.|
|Sub Category:||3.2 Corticosteroids|
|Submission Type:||Abbreviated Submission|
|Date Advice Published:||12 June 2017|
To read more Press Release articles, click here.